CN113286816B - 用于α-1-抗胰蛋白酶病症的组合物和方法 - Google Patents

用于α-1-抗胰蛋白酶病症的组合物和方法 Download PDF

Info

Publication number
CN113286816B
CN113286816B CN201980084112.0A CN201980084112A CN113286816B CN 113286816 B CN113286816 B CN 113286816B CN 201980084112 A CN201980084112 A CN 201980084112A CN 113286816 B CN113286816 B CN 113286816B
Authority
CN
China
Prior art keywords
leu
glu
lys
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980084112.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN113286816A (zh
Inventor
A·萨托
M·德苏扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spencer Therapy Co ltd
Original Assignee
Spencer Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spencer Therapy Co ltd filed Critical Spencer Therapy Co ltd
Publication of CN113286816A publication Critical patent/CN113286816A/zh
Application granted granted Critical
Publication of CN113286816B publication Critical patent/CN113286816B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980084112.0A 2018-10-29 2019-10-29 用于α-1-抗胰蛋白酶病症的组合物和方法 Active CN113286816B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752182P 2018-10-29 2018-10-29
US62/752,182 2018-10-29
PCT/US2019/058673 WO2020092448A1 (en) 2018-10-29 2019-10-29 Compositions and methods for alpha-1-antitrypsin disorders

Publications (2)

Publication Number Publication Date
CN113286816A CN113286816A (zh) 2021-08-20
CN113286816B true CN113286816B (zh) 2025-04-04

Family

ID=68771752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980084112.0A Active CN113286816B (zh) 2018-10-29 2019-10-29 用于α-1-抗胰蛋白酶病症的组合物和方法

Country Status (9)

Country Link
US (2) US12497441B2 (https=)
EP (1) EP3873926A1 (https=)
JP (2) JP7731288B2 (https=)
KR (1) KR20210111245A (https=)
CN (1) CN113286816B (https=)
AU (1) AU2019369403B2 (https=)
BR (1) BR112021008200A2 (https=)
CA (1) CA3117961A1 (https=)
WO (1) WO2020092448A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200385713A1 (en) 2019-01-22 2020-12-10 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
CA3127243A1 (en) 2019-01-22 2020-07-30 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP3914260A4 (en) 2019-01-22 2023-05-17 Korro Bio, Inc. RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE
KR20230033651A (ko) * 2020-05-28 2023-03-08 코로 바이오, 인크. Serpina1의 adar-매개 편집을 위한 방법 및 조성물
AU2021375735A1 (en) * 2020-11-06 2023-06-08 Aatec Medical Gmbh A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
US20240101630A1 (en) * 2020-12-18 2024-03-28 Cullinan Amber Corp. Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof
CN117942275A (zh) * 2022-10-31 2024-04-30 康码（上海）生物科技有限公司 一种基于病毒阻断剂的洗手液及其应用
CN121100127A (zh) * 2023-05-05 2025-12-09 保罗·托马斯·金 新型治疗性多肽
EP4730999A1 (en) * 2023-06-22 2026-04-29 AATEC Medical GmbH Recombinant aat from yeast to treat transplants
EP4480493A1 (en) 2023-06-22 2024-12-25 AATEC Medical GmbH A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917563A (zh) * 2011-06-28 2014-07-09 英伊布里克斯有限责任公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000007I2 (de) 1986-04-09 2010-12-30 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6632637B1 (en) 1999-10-13 2003-10-14 Immunex Corporation Vectors and methods for recombinant protein expression
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003066824A2 (en) 2002-02-07 2003-08-14 Aventis Behring Gmbh Albumin-fused kunitz domain peptides
EP2287326A1 (en) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
US20070269442A1 (en) 2006-05-19 2007-11-22 Robert J. Webber Chimeric monoclonal antibody recognizing iNOS
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2008086524A2 (en) 2007-01-11 2008-07-17 University Of Florida Research Foundation, Inc. Alpha-1-antitrypsin variants and uses thereof
KR100992526B1 (ko) 2007-11-21 2010-11-05 한국과학기술연구원 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법
US8341615B2 (en) 2008-07-11 2012-12-25 International Business Machines Corporation Single instruction multiple data (SIMD) code generation for parallel loops using versioning and scheduling
JP5727459B2 (ja) 2009-04-22 2015-06-03 アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
US10400029B2 (en) * 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CA2896951A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
GB201322091D0 (en) * 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
EP3600345A4 (en) 2017-03-29 2021-01-06 Cornell University OXIDATION-RESISTANT AAT GENE THERAPY
CN110092828B (zh) 2018-01-31 2021-08-24 北京大学 重组突变体α1-抗胰蛋白酶及其制备和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103917563A (zh) * 2011-06-28 2014-07-09 英伊布里克斯有限责任公司 丝氨酸蛋白酶抑制蛋白融合多肽及其使用方法
WO2016069574A1 (en) * 2014-10-27 2016-05-06 Inhibrx Lp Serpin fusion polypeptides and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Altered native stability is the dominant basis for susceptibility of α1-antitrypsin mutants to polymerization;James A. IRVING等;《Biochem. J. 》;第460卷;第104页左栏EXPERIMENTAL部分，第109页右栏第1-2段，表3-4 *
Distribution of the Native Strain in Human a1-Antitrypsin and Its Association with Protease Inhibitor Function;Eun Joo Seo等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;第275卷(第22期);表1、第16908页左栏第2段 *

Also Published As

Publication number Publication date
US20210388059A1 (en) 2021-12-16
US20260092099A1 (en) 2026-04-02
CN113286816A (zh) 2021-08-20
WO2020092448A1 (en) 2020-05-07
KR20210111245A (ko) 2021-09-10
AU2019369403B2 (en) 2025-04-17
AU2019369403A1 (en) 2021-05-20
US12497441B2 (en) 2025-12-16
JP7731288B2 (ja) 2025-08-29
JP2024123234A (ja) 2024-09-10
JP2022509517A (ja) 2022-01-20
EP3873926A1 (en) 2021-09-08
BR112021008200A2 (pt) 2021-12-14
CA3117961A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
CN113286816B (zh) 用于α-1-抗胰蛋白酶病症的组合物和方法
JP6674604B2 (ja) セルピン融合ポリペプチド及びその使用方法
KR102067394B1 (ko) 신경학적 염증성 장애의 치료를 위한 인자 ｘｉｉ 억제제
JP6737781B2 (ja) セルピン融合ポリペプチド及びその使用方法
JP2008504806A (ja) Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
EP4008731A1 (en) Fusion protein of eta antibody and tgf-beta trap and pharmaceutical composition and application thereof
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
CN110590959B (zh) 重组犬pd-1融合蛋白及其制备方法与应用
EP4464329A1 (en) Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonist
CN117396519A (zh) 肾脏活性融合蛋白以及使用其的治疗方法
KR20180003677A (ko) 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물
RU2846432C2 (ru) Слитые серпиновые полипептиды и способы их применения
IL324787A (en) Il10 inverted monomers
CN121889419A (zh) 包含robo结构域的蛋白及其医药用途
HK1197544B (en) Serpin fusion polypeptides and methods of use thereof
HK1197544A (en) Serpin fusion polypeptides and methods of use thereof
MXPA06009522A (en) Il-4/il-13 sepecific polypetides and therapeutic uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant